These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25219913)

  • 1. Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.
    Zhang CY; Zhu Y; Rui WB; Dai J; Shen ZJ
    Asian J Androl; 2015; 17(1):106-10. PubMed ID: 25219913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the serine protease kallikrein 7 and its inhibitor antileukoprotease is decreased in prostate cancer.
    Xuan Q; Yang X; Mo L; Huang F; Pang Y; Qin M; Chen Z; He M; Wang Q; Mo ZN
    Arch Pathol Lab Med; 2008 Nov; 132(11):1796-801. PubMed ID: 18976018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.
    Avgeris M; Stravodimos K; Scorilas A
    Prostate; 2011 Dec; 71(16):1780-9. PubMed ID: 21520157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker.
    Korbakis D; Gregorakis AK; Scorilas A
    Clin Chem; 2009 May; 55(5):904-13. PubMed ID: 19299547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Stromal cells inhibit Kallikrein 7 expression in the epithelial cells of benign prostate hyperplasia].
    Yang XL; Xuan Q; Huang FY; Pang YH; Mo ZN
    Zhonghua Nan Ke Xue; 2011 Apr; 17(4):305-9. PubMed ID: 21548205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
    Alinezhad S; Väänänen RM; Ochoa NT; Vertosick EA; Bjartell A; Boström PJ; Taimen P; Pettersson K
    BMC Urol; 2016 Feb; 16():10. PubMed ID: 26928323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical localization and analysis of kallikrein-related peptidase 7 and 11 expression in paired cancer and benign foci in prostate cancer patients.
    Jamaspishvili T; Scorilas A; Kral M; Khomeriki I; Kurfurstova D; Kolar Z; Bouchal J
    Neoplasma; 2011; 58(4):298-303. PubMed ID: 21520985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER.
    Saker Z; Tsintsadze O; Jiqia I; Managadze L; Chkhotua A
    Georgian Med News; 2015 Dec; (249):7-14. PubMed ID: 26719543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics.
    Kim EA; Kim YH; Kang HW; Yoon HY; Kim WT; Kim YJ; Yun SJ; Moon SK; Choi YH; Kim IY; Lee SC; Kim WJ
    J Korean Med Sci; 2015 Jul; 30(7):937-42. PubMed ID: 26130958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer.
    Kryza T; Bock N; Lovell S; Rockstroh A; Lehman ML; Lesner A; Panchadsaram J; Silva LM; Srinivasan S; Snell CE; Williams ED; Fazli L; Gleave M; Batra J; Nelson C; Tate EW; Harris J; Hooper JD; Clements JA
    Mol Oncol; 2020 Jan; 14(1):105-128. PubMed ID: 31630475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer.
    Talieri M; Mathioudaki K; Prezas P; Alexopoulou DK; Diamandis EP; Xynopoulos D; Ardavanis A; Arnogiannaki N; Scorilas A
    Thromb Haemost; 2009 Apr; 101(4):741-7. PubMed ID: 19350120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
    Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
    Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies.
    Li X; Liu J; Wang Y; Zhang L; Ning L; Feng Y
    Cancer Sci; 2009 Apr; 100(4):601-7. PubMed ID: 19453546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.
    Gong W; Liu Y; Diamandis EP; Kiechle M; Bronger H; Dorn J; Dreyer T; Magdolen V
    J Ovarian Res; 2020 Oct; 13(1):125. PubMed ID: 33087135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TUG1 promotes the development of prostate cancer by regulating RLIM.
    Guo BH; Zhao Q; Li HY
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1926-1933. PubMed ID: 30915735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation.
    Yu X; Xu X; Han B; Zhou R
    Pathol Oncol Res; 2009 Mar; 15(1):91-6. PubMed ID: 18752043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer.
    He HC; Bi XC; Zheng ZW; Dai QS; Han ZD; Liang YX; Ye YK; Zeng GH; Zhu G; Zhong WD
    Med Oncol; 2009; 26(3):303-8. PubMed ID: 19003546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.
    Hillebrand AC; Pizzolato LS; Neto BS; Branchini G; Brum IS
    PLoS One; 2018; 13(7):e0200613. PubMed ID: 30028845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.